3.39MMarket Cap0.14P/E (TTM)
3.140High2.860Low104.17KVolume2.970Open2.840Pre Close311.99KTurnover9.18%Turnover RatioLossP/E (Static)1.15MShares142.50052wk High0.51P/B3.35MFloat Cap2.54052wk Low--Dividend TTM1.13MShs Float1590.000Historical High--Div YieldTTM9.86%Amplitude2.540Historical Low2.995Avg Price1Lot Size
Tharimmune Stock Forum
loading...
Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104
Tharimmune (NASDAQ:THAR), a clinical-stage biotech company, has launched a new website at www.tharimmune.com. The redesigned platform offers comprehensive information about the company's research, clinical trials, and corporate developments. CEO Randy Milby emphasized the website's role in enhancing communication with stakeholders.
Concurrently, Tharimmune is continui...
Easy to get in, hard to get out.
Skip this.
Tharimmune Announces $2.08 Million Private Placement
Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
Tharimmune has received positive feedback from the FDA for its Phase 2 clinical trial of TH104, a transmucosal buccal film containing nalmefene, for treating moderate-to-severe pruritus in primary biliary cholangitis (PBC). This feedback supports Tharimmune's plan to pursue a 505(b)(2) approval pathway, al...
No comment yet